Nektar drug fails late-stage study in breast cancer patients

March 17, 2015 8:53 PM

2 0

(Reuters) - Nektar Therapeutics said its experimental drug failed to meet the main goal in previously treated patients with advanced breast cancer in a late-stage study.

The drug, NKTR-102, provided a 2.1 month improvement in median overall survival over patients on chemotherapy in the trial, but the effect was not statistically significant, the company said.

Also read: National Cancer Institute Says Researchers Didn’t Quickly Tell FDA After Two Deaths in a Lymphoma Study

Read more

To category page